April 25, 2025 – Medtronic plc, a global leader in healthcare technology, recently received U.S. Food and Drug Administration (FDA) approval for the OmniaSecure defibrillation lead for placement within the right ventricle. The lead, built on the highly reliable SelectSecure Model 3830 pacing lead and delivered via catheter, builds on the Medtronic portfolio of lead solutions designed for precise delivery and placement.